Expert Insights

Amer Zeidan, MBBS, highlights his treatment choices for the case of a 74-year-old patient diagnosed with lower-risk myelodysplastic syndrome (MDS).

At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

Nagesh Kalakonda, MD, discusses final results from the L-MIND study, in which the combination of tafasitamab plus lenalidomide demonstrated durable responses and curative potential for patients with R/R DLBCL.

Javier Bolaños Meade, MD, presents insights from a phase 3 trial on post-transplantation cyclophosphamide, tacrolimus, mycophenolate and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease.

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.